Hanekamp Annemarie 4
4 · BioNTech SE · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
BioNTech (BNTX) CCO Annemarie Hanekamp Receives Award
What Happened
Annemarie Hanekamp, Chief Commercial Officer of BioNTech SE (BNTX), was granted two derivative equity awards on 2026-05-12 totaling 22,655 units: 12,586 and 10,069 units. The Form 4 reports $0.00 per unit (awards/grants), i.e., these were compensation awards rather than purchases or sales. One award is documented as an option (exercise price noted in the filing as EUR 89.38) and the other as performance share units (PSUs).
Key Details
- Transaction date: 2026-05-12; Form 4 filed 2026-05-13 (timely filing).
- Awards: 12,586 units and 10,069 units (total 22,655). Reported price: $0.00 (award/grant).
- Option exercise price (per footnote): EUR 89.38; subject to adjustment per filing (see footnote).
- Vesting/exercise: Footnotes indicate annual vesting in equal installments over four years, with awards becoming exercisable/settleable four years after grant, subject to continued service and performance conditions.
- Settlement: Option/award may be settled in ordinary shares, ADSs and/or cash (at the supervisory board’s election).
- Shares owned after transaction: Not specified in the summary provided (check full Form 4 for post-transaction holdings).
Context
These are derivative compensation awards (an option and PSUs) common in executive pay packages. The PSUs are tied to performance targets based on BioNTech’s share price relative to the Nasdaq Biotechnology Index (or a successor index), so final payout depends on meeting those targets and continued service. Because these are grants (not open-market purchases or sales), they do not represent an immediate cash investment or liquidation by the insider.
Insider Transaction Report
- Award
Option (right to buy)
[F1][F2][F3]2026-05-12+12,586→ 12,586 totalFrom: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (12,586 underlying) - Award
Performance Share Unit
[F4]2026-05-12+10,069→ 10,069 totalExercise: $0.00From: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (10,069 underlying)
Footnotes (4)
- [F1]The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- [F2]The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- [F3]The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- [F4]Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.